FIND DOCTORS
-
Name: Tang Jie
Department: GYNECOLOGIC ONCOLOGY
Title:Associate ProfessorEducation & Professional Experience 2010 Sister Institution Assistant, Department of Gynecology Oncology, M.D. Anderson Cancer Center, The University of Texas.
2005- Associated Professor, Department of Gynecologic Oncology, Fudan University Cancer Hospital.
2001-2004 Doctor of Medicine, Department of Oncology, Fudan University, Shanghai.
1999-2005 Attending physician, Department of Gynecologic Oncology, Fudan University Cancer Hospital.
1995-1998 Master of Science, Department of Oncology, Shanghai Medical University, Shanghai.
1993-1999 Resident, Department of Gynecologic Oncology, Shanghai Medical University Cancer Hospital.
1987-1993 Bachelor of Science, Department of Medical Science, Shanghai Medical University, Shanghai.
Specialty Ovarian cancer, High risk Gestational Trophoblastic Neoplasms, Cervical cancer, Endometrial cancer Research Ovarian cancer, High risk Gestational Trophoblastic Neoplasms Publication Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J. Surg. Oncol. 2010; 101:244-250
Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur J Surg Oncol. 2009 Oct;35(10):1105-8.
Tang J, Cai SM, Huang X, et al. Integrated chemotherapy and radiotherapy in the management of recurrent epithelial ovarian cancer. Tumor, 2007,27(8):638-641,650
Tang J, Cai SM, Huang X, et al. Impact of whole abdomen radiation therapy integrated in the management of recurrent epithelial ovarian cancer. China Oncology, 2006,16(11):931-5
Zang RY, Li ZT, Tang J, et al. Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer. World J Surg Oncol. 2006, 9(4):4.
Tang J, Cai SM, Yang WT, et al. The expression of metastasis suppressor gene KAI1 and its prognostic value in epithelial ovarian cancer. National Medical Journal of China ,2005,85(2):115-7
Tang J, Cai SM, Zangt RY, et al. The Significance of abdominal residue after primary cytoreductive surgery for stage Ⅲ ovarian cancer. China Oncology, 2004,14(1):31-5
Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, Teng NN. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer, 2004,100(6):1152-61
Wang H, Sun J, Tang J. Sentinel lymph node detection by dye method in patients with cervical cancer. U.S.C J Lym Oncol, 2004,3(3):147-50
Tang J, Cai SM, Zangt RY, et al. The Results of secondary cytoreductive surgery and second-line chemotherapy for patients with epithelial ovarian cancer. China Oncology, 2003,9(3): 189-92
Tang J, Cai SM, Huang X, et al. A clinical analysis of ovarian clear cell carcinoma. Tumor, 2001,21(3): 188-90
Tang J, Cai SM, Fan JX, et al. Refractory ovarian cancinoma treated with Vindesine, Aclarubicin, mitomycin (VAM). Tumor, 2001,21(1): 51-3
Tang J, Cai SM, Fan JX, et al. A Clincal Report of Drug-resistant Malignent Gynecologic Cancer Treated With Paclitaxel. Zhejiang Tumor, 2000,6(2): 69-71
Tang J, Cai SM, Shi DR. Prognostic role of P21WAF1in ovarian carcinoma. Tumor, 2000,20(2): 121-3
Tang J, Cai SM, Fan JX, et al. A clinical report of refractory ovarian cancinoma treated with Vindesine, Aclarubicin, mitomycin (VAM). China Oncology, 1999,9(3): 189-92Awards Collaborator of Shanghai Science and Technology Progress Award, Third Prize, Shanghai (9312007Y0962), Shanghai Government, 2007 Out-patient Schedule Friday morning
